Site is Being Upgraded

A live -attenuated pneumococcal vaccine-based therapy for lowering cholesterol, and triglycerides levels: Repurposing the live -attenuated pneumococcal vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): Live -attenuated pneumococcal vaccine decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via down-regulation of its target gene, 12/September/2018, 11.58 pm

Induction of the PD-1 pathway for Pain therapy: Dexmedetomidine (Trade name: Precedex), a general anesthetic,  increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 12/September/2018, 11.48 am
September 12, 2018
Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Mibolerone (Trade name: Cheque drops and Matenon), an anabolic-androgenic steroid, increases the expression of tumor suppressors genes, such as TMP1, BTG2, p53,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 13/September/2018, 12.04 am
September 12, 2018
Show all

The significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


Research findings to Therapeutic opportunity:

This study suggests, first the first time, a live -attenuated pneumococcal vaccine-based therapy for lowering cholesterol and triglyceride levels and to treat Non-alcoholic fatty liver disease (NAFLD). Influenza A (H1N1)-vaccine  has been shown to protect against cardiovascular diseases, stroke, and others. However, the mechanism of action remains largely unknown.

Live -attenuated pneumococcal vaccine, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, Live -attenuated pneumococcal vaccine, either alone or in combination with other drugs, may be used to treat NAFLD.

Figure 1. Mechanistic insights into how  Live -attenuated pneumococcal vaccine decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD.

Figure 2. Repurposing the Live -attenuated pneumococcal vaccine into a cholesterol-lowering vaccine. Live -attenuated pneumococcal vaccine lowers cholesterol and triglyceride levels and attenuates NAFLD through down-regulation of HMGCR

[easy_payment currency=”USD”]

 

 

 

 

 

 

 

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Live -attenuated pneumococcal vaccine decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., A live -attenuated pneumococcal vaccine-based therapy for lowering cholesterol, and triglycerides levels: Repurposing the live -attenuated pneumococcal vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): Live -attenuated pneumococcal vaccine decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via down-regulation of its target gene, 12/September/2018, 11.58 pm, 12/September/2018, 11.58 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.